Financials data is unavailable for this security.
View more
Year on year Outlook Therapeutics Inc had revenues remain flat at 0.00, though the company grew net income from a loss of 66.05m to a smaller loss of 58.98m.
Gross margin | -- |
---|---|
Net profit margin | -- |
Operating margin | -- |
Return on assets | -205.48% |
---|---|
Return on equity | -- |
Return on investment | -- |
More ▼
Cash flow in USDView more
In 2023, Outlook Therapeutics Inc increased its cash reserves by 34.46%, or 6.00m. Cash Flow from Financing totalled 48.97m or -- of revenues. In addition the company used 42.97m for operations while cash used for investing totalled .
Cash flow per share | -5.71 |
---|---|
Price/Cash flow per share | -- |
Book value per share | -3.57 |
---|---|
Tangible book value per share | -3.57 |
More ▼
Balance sheet in USDView more
Current ratio | 1.07 |
---|---|
Quick ratio | -- |
Total debt/total equity | -- |
---|---|
Total debt/total capital | -- |
More ▼